Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-driven CARCIK-CD19 cell therapy in relapsed/refractory BCP-ALL
2020-005025-85Phase 2Active
- Sponsor
- Fondazione Matilde Tettamanti
- Start
- Jun 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CARCIK-CD19 in acute lymphoblastic leukemia (ALL), sponsored by Fondazione Matilde Tettamanti. Primary endpoint: Overall response rate at day 28. Started Jun 2021; status: active.
02
Drugs
CARCIK-CD19
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2020-005025-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005025-85.